An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels

被引：23
|
作者：
Roesner, Thies [1 ,2 ]
Derer, Stefanie [1 ,2 ]
Kellner, Christian [1 ,2 ]
Dechant, Michael [2 ,3 ]
Lohse, Stefan [1 ,2 ]
Vidarsson, Gestur [4 ,5 ]
Peipp, Matthias [1 ,2 ]
Valerius, Thomas [1 ,2 ]
机构：
[1] Univ Kiel, Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Univ Kiel, Dept Med Nephrol & Hypertens 4, Kiel, Germany
[4] Sanquin Res, Dept Expt Immunohaematol, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 161卷 / 02期
关键词：
rituximab; IgG3; complement-dependent cytotoxicity; chronic lymphocytic leukaemia; MONOCLONAL-ANTIBODIES; LYMPHOMA;
D O I：
10.1111/bjh.12209
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：282 / 286
页数：5
相关论文
共 32 条
  • [11] An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity
    Wirt, Tim
    Rosskopf, Sophia
    Rosner, Thies
    Eichholz, Klara Marie
    Kahrs, Anne
    Lutz, Sebastian
    Kretschmer, Anna
    Valerius, Thomas
    Klausz, Katja
    Otte, Anna
    Gramatzki, Martin
    Peipp, Matthias
    Kellner, Christian
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (05) : 292 - 300
  • [12] Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity
    Nowis, Dominika
    Winiarska, Magdalena
    Bil, Jacek
    Muchowicz, Angelika
    Wanczyk, Malgorzata
    Glodkowska-Mrowka, Eliza
    Bojarczuk, Kamil
    Firczuk, Malgorzata
    Wilczek, Ewa
    Wachowska, Malgorzata
    Chlebowska, Justyna
    Dwojak, Michal
    Miaczynska, Marta
    Stoklosa, Tomasz
    Golab, Jakub
    BLOOD, 2011, 118 (21) : 1590 - 1590
  • [13] TG20, a Transgenically-Derived Anti-CD20 Monoclonal Antibody, Exhibits Enhanced Cytotoxicity Against Cells with Low Levels of CD20
    Echelard, Yann
    Pollock, Daniel P.
    De Coupade, Catherine
    Olivier, Aurelie Groseil
    Brune, Frederique
    Chen, LiHow
    Masiello, Nicholas C.
    Williams, Jennifer L.
    Gavin, William G.
    Chtourou, Sami
    Meade, Harry M.
    BLOOD, 2011, 118 (21) : 1174 - 1174
  • [14] CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I
    Lindorfer, Margaret A.
    Beum, Paul V.
    Taylor, Ronald P.
    ANTIBODIES, 2013, 2 (04): : 598 - 616
  • [15] Type I CD20 antibodies take over the B-cell receptor for complement-dependent cytotoxicity (CDC) of malignant B cells
    Engelberts, Patrick J.
    Voorhorst, Marleen
    Schuurman, Janine
    van Meerten, Tom
    Bakker, Joost M.
    Vink, Tom
    Mackus, Wendy J. M.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    Beurskens, Frank J.
    IMMUNOBIOLOGY, 2012, 217 (11) : 1218 - 1218
  • [16] Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity
    van Meerten, Tom
    van Rijn, Rozemarijn S.
    Hol, Samantha
    Hagenbeek, Anton
    Ebeling, Saskia B.
    CLINICAL CANCER RESEARCH, 2006, 12 (13) : 4027 - 4035
  • [17] Point mutation of C-terminal region of CD20 molecule predicts rituximab-induced complement-dependent cytotoxicity and clinical response to rituximab in non-Hodgkin's lymphoma.
    Terui, Y.
    Mishima, Y.
    Mishima, Y.
    Yokoyama, M.
    Hatake, K.
    Sugimura, N.
    Kojima, K.
    Sakurai, T.
    Takeuchi, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 437S - 437S
  • [18] CD20 mAb-mediated C3b deposition and complement dependent cytotoxicity of tumor cells is enhanced by blocking the action of Factor I
    Taylor, Ronald P.
    Lindorfer, Margaret A.
    Beum, Paul V.
    IMMUNOBIOLOGY, 2012, 217 (11) : 1148 - 1148
  • [19] Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression
    Shimada, Kazuyuki
    Tomita, Akihiro
    Saito, Shigeki
    Kiyoi, Hitoshi
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (03) : 455 - 457
  • [20] Anti-CD20-interferon-alpha fusion protein has superior in vivo activity against human B-cell lymphomas compared to rituximab and enhanced complement-dependent cytotoxicity in vitro
    Yamada, Reiko E.
    Steward, Kristopher K.
    Ngarmchamnanrith, Gataree
    Trinh, Ryan K.
    Khare, Sanjay
    Sachdev, Raj
    Grewal, Iqbal S.
    Morrison, Sherie L.
    Timmerman, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
1234